Chugai Pharmaceutical Co., Ltd.

OTCPK:CHGC.F Stock Report

Market Cap: US$69.4b

Chugai Pharmaceutical Valuation

Is CHGC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHGC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHGC.F ($40.45) is trading below our estimate of fair value ($44.92)

Significantly Below Fair Value: CHGC.F is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHGC.F?

Key metric: As CHGC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHGC.F. This is calculated by dividing CHGC.F's market cap by their current earnings.
What is CHGC.F's PE Ratio?
PE Ratio27.6x
EarningsJP¥386.96b
Market CapJP¥10.69t

Price to Earnings Ratio vs Peers

How does CHGC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CHGC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.8x
ZTS Zoetis
33.2x9.9%US$79.8b
PFE Pfizer
34.7x16.8%US$145.4b
MRK Merck
21.1x15.6%US$250.9b
RPRX Royalty Pharma
10.3x6.3%US$11.7b
CHGC.F Chugai Pharmaceutical
27.6x6.2%US$10.7t

Price-To-Earnings vs Peers: CHGC.F is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the peer average (24.8x).

Price to Earnings Ratio vs Industry

How does CHGC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.5xn/aUS$1.87b
PROC Procaps Group
2.7xn/aUS$103.80m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$10.11m
EDXC Endexx
0.9xn/aUS$5.34m
CHGC.F 27.6xIndustry Avg. 19.5xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHGC.F is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the US Pharmaceuticals industry average (20.5x).

Price to Earnings Ratio vs Fair Ratio

What is CHGC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHGC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CHGC.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHGC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$40.45
US$46.87
+15.9%
19.0%US$64.22US$29.19n/a14
Nov ’25US$45.22
US$46.48
+2.8%
19.7%US$64.58US$29.35n/a14
Oct ’25n/a
US$46.45
0%
17.4%US$59.25US$31.37n/a15
Sep ’25US$50.31
US$44.83
-10.9%
17.1%US$58.14US$30.78n/a14
Aug ’25US$39.04
US$40.57
+3.9%
17.7%US$55.46US$29.36n/a14
Jul ’25US$35.25
US$36.97
+4.9%
15.3%US$50.35US$27.97n/a14
Jun ’25n/a
US$38.26
0%
15.5%US$51.87US$28.81n/a14
May ’25US$32.43
US$38.69
+19.3%
15.5%US$51.43US$28.57n/a14
Apr ’25n/a
US$41.13
0%
14.4%US$50.04US$30.39n/a14
Mar ’25US$39.99
US$39.13
-2.2%
12.2%US$49.43US$30.02n/a14
Feb ’25n/a
US$36.38
0%
12.4%US$43.05US$29.39n/a14
Jan ’25US$37.00
US$37.30
+0.8%
11.7%US$43.86US$30.42n/a14
Dec ’24US$33.23
US$33.77
+1.6%
12.0%US$40.68US$25.09n/a14
Nov ’24n/a
US$32.48
0%
10.7%US$36.23US$24.82US$45.2214
Oct ’24n/a
US$31.12
0%
10.4%US$36.13US$24.76n/a13
Sep ’24US$30.00
US$31.30
+4.3%
10.2%US$35.66US$25.37US$50.3115
Aug ’24US$29.36
US$31.41
+7.0%
9.8%US$36.67US$25.89US$39.0415
Jul ’24n/a
US$30.25
0%
9.1%US$34.56US$25.39US$35.2515
Jun ’24n/a
US$29.90
0%
11.3%US$34.89US$23.50n/a15
May ’24US$26.00
US$31.20
+20.0%
12.3%US$36.59US$24.64US$32.4314
Apr ’24US$24.91
US$31.07
+24.7%
12.7%US$37.70US$24.88n/a13
Mar ’24n/a
US$30.88
0%
10.8%US$36.73US$25.71US$39.9913
Feb ’24n/a
US$33.41
0%
15.0%US$46.20US$27.72n/a13
Jan ’24US$25.60
US$31.85
+24.4%
15.0%US$43.58US$26.15US$37.0013
Dec ’23n/a
US$31.45
0%
15.0%US$42.74US$25.64US$33.2313
Nov ’23n/a
US$30.06
0%
14.8%US$40.70US$24.42n/a13

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%